JF
PBYI icon

Jump Financial’s Puma Biotechnology PBYI Stock Holding History

Jump Financial’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-41,658
Closed -$221K – 2143
2024
Q1 		$221K Sell
41,658
-15,542
-27% -$83.7K 0.01% 1628
2023
Q4 		$248K Buy
57,200
+32,510
+132% +$108K 0.01% 1446
2023
Q3 		$64.9K Buy
24,690
+5,190
+27% +$17.7K ﹤0.01% 1725
2023
Q2 		$68.8K Sell
19,500
-15,400
-44% -$48K ﹤0.01% 1703
2023
Q1 		$108K Sell
34,900
-11,934
-25% -$45K ﹤0.01% 1429
2022
Q4 		$198K Buy
+46,834
New +$162K 0.01% 1297
2022
Q2 		– Sell
-39,700
Closed -$114K – 1925
2022
Q1 		$114K Sell
39,700
-5,700
-13% -$14.7K ﹤0.01% 1397
2021
Q4 		$138K Buy
+45,400
New +$197K 0.01% 1175
2020
Q4 		– Sell
-23,000
Closed -$232K – 1121
2020
Q3 		$232K Buy
+23,000
New +$234K 0.05% 592

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jump Financial's PBYI Position: Q2 2024 in Review

Jump Financial sold out of Puma Biotechnology (PBYI) in Q2 2024, closing a stake of 41,658 shares — an estimated $221K sold.

Jump Financial first reported a position in PBYI in Q3 2020 and held it in 9 quarters. The position peaked at $248K in Q4 2023. 99 funds tracked by Wall St. Rank hold PBYI as of Q2 2024.

  • Jump Financial reported no remaining Puma Biotechnology position as of Q2 2024 after selling out during the quarter.
  • Jump Financial sold 41,658 Puma Biotechnology shares in Q2 2024, an estimated $221K.
  • Jump Financial first reported a position in Puma Biotechnology in Q3 2020 and held it in 9 quarters.
  • Jump Financial's Puma Biotechnology position peaked at $248K in Q4 2023.
  • 99 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2024.

Based on Jump Financial's 13F filing for Q2 2024, filed 14 Aug 2024.